News

CROWN LABORATORIES ACQUIRES BELLUS MEDICAL

Posted by admin on September 27, 2018
Comments Off on CROWN LABORATORIES ACQUIRES BELLUS MEDICAL
Category: News

FOR IMMEDIATE RELEASE

CROWN LABORATORIES ACQUIRES BELLUS MEDICAL

Hildred Capital Portfolio Company Establishes Aesthetics Division
with Innovative, Non-Invasive Product Line

September 27, 2018 – Johnson City, TN & Addison, TX – Crown Laboratories, Inc. (“Crown Laboratories”), a leading, fully integrated, specialty pharmaceutical company and Hildred Capital Partners LLC (“Hildred”) portfolio company, today announced it has acquired Bellus Medical, a leader in medical aesthetics treatments dedicated to delivering innovative repair and restoration products to aesthetic practices around the world.

Bellus’s non-invasive products give it a unique position in aesthetics, providing a range of products that draw first-time consumers to leading physician-directed practices globally. Most notable among its products is the SkinPen® – a medical grade microneedling device used exclusively by healthcare professionals to improve the appearance of facial acne scars – the first microneedling device in the industry to be granted clearance and marketing authorization by the U.S. Food and Drug Administration (FDA) for this indication. Bellus’s full line of innovative products and devices includes:

• SkinPen®: the first ever FDA-cleared microneedling device for the treatment of acne scarring
• Skinfuse: post-microneedling protocol
• Allumera: light-activated cream
• ProGenTM / RegenLab: platelet-rich plasma systems

Bellus Medical will become the new Aesthetics Division of Crown Laboratories and be renamed Bellus Aesthetics. Bellus will continue to be based in Dallas, Texas and operate as a wholly-owned subsidiary of Crown Laboratories. Bellus CEO Joe Proctor will become President of Crown’s Aesthetics Division and join the Crown Board of Directors.

“Partnering with Bellus is a truly exciting and significant first step in building our Aesthetics Division,” said Jeff Bedard, Crown Laboratories President and CEO. “Bellus has assembled a truly impressive team with an enviable track record of innovation in aesthetics, exemplified by the SkinPen®, the first ever FDA-cleared microneedling device for acne scarring. We believe there is a tremendous opportunity for us in aesthetics, and with Bellus as the cornerstone of our new division, we expect to expand our portfolio meaningfully in the years ahead.”

“We are thrilled to have found such a compelling opportunity with a partner that shares our vision and approach to growing the business and improving patient outcomes,” said Joe Proctor, Bellus Medical CEO. “The Crown Labs organization is culturally compatible and brings us the additional resources we need to expand our infrastructure, support future growth, and better serve our valued network of providers. This transaction represents a unique opportunity to build Bellus into an elite aesthetics company and we look forward to joining with our new colleagues and to building the Crown aesthetics franchise.”

“On behalf of Hildred, I am delighted to work with Crown on launching its new Aesthetics Division and to welcome Joe and his colleagues to the team,” said David Solomon, Hildred Partner and Chairman of the Board for Crown Laboratories. “With its unique market position and portfolio, led by the first ever recognized Class II microneedling device, Bellus represents an exciting opportunity for Crown, complements its current skincare offering and expands its potential to grow and drive future consolidation. We will continue to look for distinct and attractive opportunities to build on Crown’s consumer healthcare and prescription product lines – and now its aesthetic product line – with the launch of this new division.”

Financial terms of the transaction were not disclosed. Lowenstein Sandler, LLP acted as legal advisor to Crown Laboratories and Hildred, while Hayfin Capital Management, LLP provided debt financing in connection with the transaction. Piper Jaffray and Perkins Coie served as financial and legal advisors, respectively, to Bellus Medical.

Earlier this month, Montreux Equity Partners completed a growth capital financing in Crown Laboratories out of its new healthcare growth capital fund, Montreux Growth Partners II, L.P. With the financing, Crown continues to broaden its distribution across existing channels, and add new product lines to support its growth as a leading player focused on dermatology.

About Crown Laboratories, Inc.
Crown Laboratories, Inc. is a privately held, fully integrated, specialty pharmaceutical company, focused in dermatology and committed to developing and providing a diverse portfolio of pharmaceutical and consumer products, which improve the quality of life for its customers. Crown Laboratories is an innovative company, whose Blue Lizard Australian sunscreen, Vita Liberata organic sunless tanning and skincare, and robust portfolio of dermatological products have paved the way for Crown Laboratories’ rapid growth. Crown Laboratories’ prescription portfolio includes key branded products AlaScalp, AlaQuin and Tri-Derm. For more information about Crown Laboratories or its products, visit www.crownlaboratories.com.

About Hildred Capital Partners
Hildred Capital Partners, LLC is a private investment firm that invests in a broad range of securities, including equity and debt, across geographies and sectors, on both an actively and passively managed basis. Founded in 2014, Hildred has a particular interest in private equity, including situations where the principals can apply their extensive management experience to help a company reach its full potential. Hildred is headed by Howard Solomon, former CEO of Forest Laboratories, and David Solomon, former Senior Vice President, Corporate Development & Strategic Planning at Forest Laboratories, together with Andrew Goldman, the firm’s Chief Investment Officer.

About Bellus Medical
Bellus Medical, headquartered in Addison, TX, is an industry leader in medical aesthetics with an unmatched reputation of providing the highest levels of safe and effective products and the most innovative technology on the market. Founded in 2012, Bellus quickly became an industry pioneer with the introduction of its flagship product SkinPen®, a state-of-the-art microneedling device, which was the first ever FDA-cleared medical grade microneedling device on the market. Bellus’ product portfolio continually expands with unique and differentiated products developed to enhance the patient experience and represent a significant business opportunity for medical practices. Built upon three guiding principles – technology, education and customer service – Bellus is much more than a supplier to aesthetic practices, it is a trusted business partner. To learn more about Bellus Medical, visit www.BellusMedical.com.

About Montreux Equity Partners
Montreux Equity Partners is dedicated to making growth capital investments in high growth, category-leading companies with products, technologies and services that are advancing health. Founded in 1993, Montreux has invested in more than 60 companies, including MINDBODY (Nasdaq: MB), Glaukos (NYSE: GKOS), Tobira Therapeutics (acquired by Allergan), MAKO Surgical (acquired by Stryker), SkinMedica (acquired by Allergan) and Renal CarePartners (acquired by Ambulatory Services of America). Montreux is based in San Francisco, CA, and is currently investing out of its second healthcare growth capital fund, Montreux Growth Partners II, L.P. For more information about Montreux Equity Partners, visit www.mepvc.com.

Forward Looking Statements
In this press release, the use of words such as “expect,” “anticipate,” “possible,” “potential,” “believe,” “commit,” “intend,” “continue,” “may,” “would,” “could,” “should,” or similar expressions is intended to identify forward-looking statements that represent Crown Laboratories management’s current judgment about possible future events. We believe these judgments are reasonable, but these statements are not guarantees of any events or results, and actual results may differ materially due to a variety of important factors. Such risks and uncertainties may include, but are not limited to: the satisfaction of closing conditions to the investment by Hildred; the possibility that the transaction will not be completed or, if completed, not completed in the expected timeframe; the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; and adverse litigation or government action. Crown Laboratories undertakes no obligation to update the information contained in this release.

Contact:
For Crown Laboratories:
Libby Erwin, 423-630-2269
lerwin@crownlaboratories.com
or
For Hildred:
Reevemark
Hugh Burns/Molly Curry, 212-433-4600

# # #

For the 6th Consecutive Year, CROWN LABORATORIES, INC. Appears on the Inc. 5000 List

Posted by admin on August 21, 2018
Comments Off on For the 6th Consecutive Year, CROWN LABORATORIES, INC. Appears on the Inc. 5000 List
Category: News

For the 6th Consecutive Year, CROWN LABORATORIES, INC. Appears on the Inc. 5000 List

August 15, 2018

JOHNSON CITY, TN – Inc. magazine today revealed that CROWN LABORATORIES, INC. is No. 3955 on its 37th annual Inc. 5000, the most prestigious ranking of the nation’s fastest-growing private companies. Only six percent of companies have made the list 6 consecutive times. Crown Laboratories, Inc. is honored to be included on the list. The list represents a unique look at the most successful companies within the American economy’s most dynamic segment – its independent small businesses. Microsoft, Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn, Yelp, Zillow and many other well-known names, gained their first national exposure as honorees on the Inc. 5000.

“Crown is incredibly honored to be recognized with this distinction for the 6th time in a row,” says Jeff Bedard, Crown Laboratories, Inc. President and CEO. “To be recognized by Inc. and to be part of the group of companies on the Inc. 5000 list is truly an honor.” “We owe a debt of gratitude to our outstanding employees, that through their hard work, made this honor happen.”

The companies on the 2018 Inc. 5000 (which are listed online at Inc.com, with the top 500 companies featured in the September issue of Inc., available on newsstands August 15) have been very competitive within their markets. The list as a whole, shows staggering growth, compared with prior lists. The 2018 Inc. 5000 achieved an astounding three-year average growth of 538.2 percent and a median rate of 171.8 percent. The Inc. 5000’s aggregate revenue was $206.1 billion in 2017, accounting for 664,095 jobs over the past three years.

Complete results of the Inc. 5000, including company profiles and an interactive database, that can be sorted by industry, region and other criteria, can be found at www.inc.com/inc5000.

About Crown Laboratories, Inc.

Crown Laboratories, Inc. is a privately held, fully integrated, specialty pharmaceutical company committed to developing and providing a diverse portfolio of pharmaceutical and consumer products, which improve the quality of life for its customers. Crown Laboratories, Inc. is an innovative company on the move, whose Blue Lizard Australian Sunscreen and robust portfolio of dermatological products have paved the way for Crown’s rapid growth.

For more information about Crown Laboratories or its products, visit www.crownlaboratories.com. Contact: Libby Erwin @ 423-630-2269 or lerwin@crownlaboratories.com.

CROWN LABORATORIES, INC., A HILDRED CAPITAL PARTNERS PORTFOLIO COMPANY, ACQUIRES INNOVATIVE SELF-TANNING BRAND VITA LIBERATA

Posted by admin on January 5, 2018
Comments Off on CROWN LABORATORIES, INC., A HILDRED CAPITAL PARTNERS PORTFOLIO COMPANY, ACQUIRES INNOVATIVE SELF-TANNING BRAND VITA LIBERATA
Category: News

Adds Leading, All-Natural Product Line in Sunless Tanning to Crown’s Dermatology Portfolio


NEW YORK, NY and JOHNSON CITY, TN – January [5], 2018 – Crown Laboratories, Inc. (“Crown Laboratories”), a leading, fully integrated, specialty pharmaceutical company focused in dermatology and a Hildred Capital Partners, LLC (“Hildred”) portfolio company, today announced it has acquired Vita Liberata, an Ireland-based company with advanced organic formulations, specializing in sunless tanning and skincare products.

Founded in 2003 by Alyson Hogg, Vita Liberata was the first completely non-toxic tanning brand, with a collection of odorless products free from parabens, perfume and alcohol.  Vita Liberata products employ the company’s proprietary Advoganic™ Technology, which combines cutting edge skin chemistry with highly potent organic botanicals. The technology fully releases the premium ingredients’ potential, enabling skincare benefits that are superior to those found in formulas using traditional cosmetic chemicals. Vita Liberata’s award-winning collection is sold in premium retailers across the U.S. and Europe, as well as in more than 26 countries worldwide.  The brand is the self tanner of choice for the world’s top spas, including George V Paris, St Regis, Viceroy, Ritz-Carlton and Burj Al Arab.  Ms. Hogg will stay on as President of Consumer Brands for Crown Laboratories.

“We believe the Vita Liberata product line and the company’s strength in premium retail are a terrific complement to Crown’s Blue Lizard sunscreen brand and builds on Crown’s consumer healthcare products strategy in the dermatology space,” said Jeff Bedard, Crown Laboratories President and CEO. “Alyson and her entire team have done a remarkable job disrupting the self-tanning space, and we look forward to welcoming them to the Crown family.  We will work together to continue to provide high-quality products that are at the forefront of skincare innovation.”

“The harmful effects of UVA and UVB exposure are undeniable, and skin cancer rates continue to rise worldwide,” said Alyson Hogg.  “Before Vita Liberata, few natural alternatives existed. Our ingredients are natural, certified organic and Ecocert – the purest in the tanning world. Crown and Hildred have a genuine understanding of the suncare market and a very impressive vision for the Vita Liberata brand.  We are thrilled to partner with them to leverage Crown’s strong positioning within the dermatology space and advance our mission of making self tanning a viable alternative to sun exposure for all.”

“Hildred’s goal for Crown is to build value by providing the company with the flexibility needed to foster organic growth while leveraging our experience to identify products that would complement Crown’s current offerings and contribute to accelerated growth,” said Hildred Partner David Solomon. “With a distinctive portfolio and an impressive track record of growth, Vita Liberata is a very exciting opportunity and a natural fit with Crown. As we mentioned at the time of the Crown acquisition, we will continue to actively look for interesting acquisitions, licenses and partnerships as we seek to build upon the growing overlap between medical, aesthetic, and over-the-counter dermatology,”.

Financial terms of the transaction were not disclosed. Centerview Partners served as financial advisor to Crown Laboratories, and Lowenstein Sandler and A&L Goodbody served as its legal advisors.  The Sage Group and Tughans served as financial and legal advisors, respectively, to Vita Liberata.

About Crown Laboratories, Inc.

Crown Laboratories, Inc. is a privately held, fully integrated, specialty pharmaceutical company, focused in dermatology, and committed to developing and providing a diverse portfolio of pharmaceutical and consumer products, which improve the quality of life for its customers. Crown Laboratories is an innovative company, whose Blue Lizard Australian Sunscreen and robust portfolio of dermatological products have paved the way for Crown Laboratories’ rapid growth. Crown Laboratories’ prescription portfolio includes key branded products AlaScalp, AlaQuin, Daxbia and Dermasorb HC & TA Kits. For more information about Crown Laboratories or its products, visit www.crownlaboratories.com.

About Hildred Capital Partners

Hildred Capital Partners, LLC is a private investment firm that invests in a broad range of securities, including equity and debt, across geographies and sectors, on both an actively and passively managed basis. Founded in 2014, Hildred has a particular interest in private equity, including situations where the principals can apply their extensive management experience to help a company reach its full potential. Hildred is headed by Howard Solomon, former CEO of Forest Laboratories, and David Solomon, former Senior Vice President, Corporate Development & Strategic Planning at Forest Laboratories, together with Andrew Goldman, the firm’s Chief Investment Officer.

Forward Looking Statements

In this press release, the use of words such as “expect,” “anticipate,” “possible,” “potential,” “believe,” “commit,” “intend,” “continue,” “may,” “would,” “could,” “should,” or similar expressions is intended to identify forward-looking statements that represent Crown Laboratories management’s current judgment about possible future events. We believe these judgments are reasonable, but these statements are not guarantees of any events or results, and actual results may differ materially due to a variety of important factors. Such risks and uncertainties may include, but are not limited to: the satisfaction of closing conditions to the investment by Hildred; the possibility that the transaction will not be completed or, if completed, not completed in the expected timeframe; the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; and adverse litigation or government action. Crown Laboratories undertakes no obligation to update the information contained in this release.

Media Contacts

For Crown Laboratories:
Libby Erwin
423-630-2269
lerwin@crownlaboratories.com

For Hildred:
Robin Weinberg/Pamela Greene
Sard Verbinnen & Co
212-687-8080

Hildred Capital Partners, LLC to Invest in Crown Laboratories, Inc.

Posted by admin on October 30, 2017
Comments Off on Hildred Capital Partners, LLC to Invest in Crown Laboratories, Inc.
Category: News

Hildred Capital Partners, LLC to Invest in Crown Laboratories, Inc.

Firm Will Assume Major Stake

NEW YORK & JOHNSON CITY, Tenn.–(BUSINESS WIRE)–Hildred Capital Partners, LLC (“Hildred”), the private investment firm formed by Howard Solomon and David Solomon, former Chairman and CEO of Forest Laboratories and former Senior Vice President, Corporate Development & Strategic Planning of Forest Laboratories, today announced that Hildred has entered into an agreement under which it will assume a major stake in Crown Laboratories, Inc. (“Crown Laboratories”), a leading, fully integrated, specialty pharmaceutical company based in Tennessee.

Hildred will partner with Crown Laboratories Chief Executive Officer Jeff Bedard and Chief Operating Officer Jack Songster, who will remain in their current positions and continue to be substantial equity owners in the Company.

Crown Laboratories was founded in 2000 and is known for its branded products including Blue Lizard Australian Sunscreen and medical products AlaQuin, AlaScalp and Daxbia. Crown Laboratories currently operates three distinct areas of focus related to skincare and treating skin-related conditions: Consumer Healthcare Products, Prescription Products and Contract Development and Manufacturing Services.

“Nearly forty years ago, we introduced the specialty pharma model at Forest Labs and demonstrated how that business strategy could be used to build a dynamic and responsive company that achieved great success through the development and marketing of many highly innovative products. Crown Laboratories is an ideal fit for us to employ our expertise and know-how in applying the specialty pharma model within the dermatology space. Jeff Bedard and Jack Songster have done an excellent job building Crown into the company it is today, and we are pleased to partner with them and the entire Crown team to further grow the Company and enable it to advance its mission to achieve better outcomes for patients, doctors and customers,” said Hildred Partner Howard Solomon.

“Specialty pharmaceuticals is a key area of investment for Hildred. We have been interested in the growing overlap between medical, aesthetic, and over-the-counter dermatology. We have been looking for a platform we could use to construct a business in this area, and we are impressed with the way in which Crown has brought several of these segments together in a growing business. We believe there is a substantial opportunity for us to build the company further, by fostering organic growth of the company’s existing portfolio and by leveraging our experience to identify products which would complement the company’s current offerings and contribute to further growth. We see an opportunity to be a leading consolidator in the dermatology space, and we will be actively looking for interesting acquisitions, licenses and partnership transactions,” said Hildred Partner David Solomon.

“We could not be more excited to partner with Hildred. Their track record in identifying and developing both consumer and prescription products in our industry is unmatched, and we welcome the opportunity to work with them to take what we’ve built over the last decade to the next level. We believe Howard and David and the Hildred team share our passion for understanding the underlying causes of skin-related conditions and providing solutions that improve quality of life. On behalf of the entire leadership team at Crown Laboratories, I would like to say that we are truly excited about what lies ahead for our company,” said Jeff Bedard, Crown Laboratories President and CEO.

Financial terms of the transaction were not disclosed. The transaction is expected to close in the fourth quarter of 2017. Lowenstein Sandler, LLP served as legal advisor to Hildred. Torreya Partners, LLC and Michael Best & Friedrich LLP served as financial and legal advisors, respectively, to Crown Laboratories.

About Hildred Capital Partners

Hildred Capital Partners, LLC is a private investment firm that invests in a broad range of securities, including equity and debt, across geographies and sectors, on both an actively and passively managed basis. Founded in 2014, Hildred has a particular interest in private equity, including situations where the principals can apply their extensive management experience to help a company reach its full potential. Hildred is headed by Howard Solomon, former CEO of Forest Laboratories, and David Solomon, former Senior Vice President, Corporate Development & Strategic Planning at Forest Laboratories, together with Andrew Goldman, the firm’s Chief Investment Officer.

About Crown Laboratories, Inc.

Crown Laboratories, Inc. is a privately held, fully integrated, specialty pharmaceutical company, focused in dermatology, and committed to developing and providing a diverse portfolio of pharmaceutical and consumer products, which improve the quality of life for its customers. Crown Laboratories is an innovative company, whose Blue Lizard Australian Sunscreen and robust portfolio of dermatological products have paved the way for Crown Laboratories’ rapid growth. Crown Laboratories’ prescription portfolio includes key branded products AlaScalp, AlaQuin, Daxbia and Dermasorb HC & TA Kits. For more information about Crown Laboratories or its products, visit www.crownlaboratories.com.

Forward Looking Statements

In this press release, the use of words such as “expect,” “anticipate,” “possible,” “potential,” “believe,” “commit,” “intend,” “continue,” “may,” “would,” “could,” “should,” or similar expressions is intended to identify forward-looking statements that represent Crown Laboratories management’s current judgment about possible future events. We believe these judgments are reasonable, but these statements are not guarantees of any events or results, and actual results may differ materially due to a variety of important factors. Such risks and uncertainties may include, but are not limited to: the satisfaction of closing conditions to the investment by Hildred; the possibility that the transaction will not be completed or, if completed, not completed in the expected timeframe; the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; and adverse litigation or government action. Crown Laboratories undertakes no obligation to update the information contained in this release.

Contacts

For Hildred:
Sard Verbinnen & Co
Pamela Greene/Julie Casale, 212-687-8080
or
For Crown Laboratories:
Libby Erwin, 423-630-2269
lerwin@crownlaboratories.com

CROWN LABORATORIES, INC.’s Impressive Growth Earns No. 1990 Ranking

Posted by admin on August 18, 2017
Comments Off on CROWN LABORATORIES, INC.’s Impressive Growth Earns No. 1990 Ranking
Category: News

JOHNSON CITY, TN August 16, 2017Inc. magazine today ranked CROWN LABORATORIES, INC. # 1990 on its 36th annual Inc. 5000, the most prestigious ranking of the nation’s fastest-growing private companies. Crown Laboratories, Inc. is honored to be included on the list and be considered among the top 10% of companies, who have been featured on the list for five consecutive years. The list spotlights the American economy’s most dynamic segment— its independent small and midsized businesses. Microsoft, Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn, Yelp, Zillow, and many other well-known names, gained their first national exposure as honorees.

“Crown is incredibly honored to be recognized with this distinction for the 5th time. We are committed to providing unyielding excellence to the community and the patients we treat,”

says Jeff Bedard, Crown Laboratories, Inc. President and CEO. “To be recognized by Inc. and to be part of the group of companies on Inc. 5000 list is truly an honor.”
This year’s Inc. 5000 testifies to the US entrepreneurial community’s impact and vitality. The list’s average company achieved mind-boggling three-year average growth of 481% and the companies collectively generated 619,500 jobs over the past three years. For complete results: http://www.inc.com/inc5000.

Crown’s Official Inc. 5000 Ranking: Inc. 5000- Crown Laboratories, Inc.

 About Crown Laboratories, Inc.

Crown Laboratories, Inc. is a privately held, fully integrated, specialty pharmaceutical company committed to developing and providing a diverse portfolio of pharmaceutical and consumer products, which improve the quality of life for its customers. Crown Laboratories, Inc. is an innovative company on the move, whose Blue Lizard Australian Sunscreen and robust portfolio of dermatological products have paved the way for Crown’s rapid growth.  In 2016 Crown was ranked as the 21st fastest growing company in the Tennessee region and ranked 1548 as fastest growing manufacturer nationwide in Inc. Magazine’s 2016 Inc. 5000 list. For more information about Crown Laboratories or its products, visit www.crownlaboratories.com. Contact: Libby Erwin @ 423-630-2269 or lerwin@crownlaboratories.com.